HCG Injection HCPCS Codes: J0730, J0731, J0732 for Weight Loss
HCPCS J-codes for human chorionic gonadotropin (HCG) injections marketed for weight loss:
| Code | Description | Dose |
|---|
| J0730 | HCG for weight loss, subcutaneous or intramuscular | 1 mg |
| J0731 | HCG for weight loss, subcutaneous or intramuscular | 5 mg |
| J0732 | HCG for weight loss, subcutaneous or intramuscular | 10 mg |
Critical Clinical Context
- FDA Position: HCG is not approved for weight loss. Approved only for female infertility, male hypogonadism, cryptorchidism.
- Labeling: Since 1976, FDA requires HCG weight-loss ads to state: "No substantial evidence HCG increases weight loss beyond caloric restriction."
- Protocol: Typically 125–200 IU daily + 500 kcal diet (Simeons protocol). Not evidence-based.
- Risks: OHSS, thromboembolism, androgenic effects, electrolyte imbalance.
Billing Compliance
- Use J0730–J0732 only if HCG administered for weight loss (per code descriptor).
- Document medical necessity (off-label) per payer policy; many deny.
- For FDA-approved indications, use J0725 (HCG, per 1,000 USP units) or specific diagnosis-linked codes.
- Units: 1 mg ≈ 3,000–5,000 IU (varies by product); verify vial concentration.
Alternatives
Evidence-based obesity management: lifestyle intervention, FDA-approved anti-obesity medications (semaglutide, liraglutide, phentermine-topiramate, bupropion-naltrexone), bariatric surgery.
Coding accurately reflects service; clinical appropriateness is separate.
